| Project/Area Number |
18K08397
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 54020:Connective tissue disease and allergy-related
|
|---|
| Research Institution | Juntendo University |
|---|
Principal Investigator |
Tamura Naoto 順天堂大学, 医学部, 教授 (20227284)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
多田 久里守 順天堂大学, 医学部, 准教授 (70424249)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 体軸性脊椎関節炎 / 骨新生 / IL-22 / 骨粗鬆症 / 抗RANKL抗体 / 抗sclerostin抗体 / 脊椎関節炎 / 体軸性関節 / モデルマウス / 治療 / 靭帯骨化 |
|---|
| Outline of Final Research Achievements |
Axial spondyloarthritis (ax-SpA) is a chronic inflammatory disease characterized with enthesitis and subsequent progression of new bone formation of sacroiliac joints and spine, and vertebrae are fused with syndesmophtes causing severe physical dysfunction. Since the etiology and therapeutic target of new bone formation in axSpA is unknown, we examined whether IL-22 inhibition prevented new bone formation in axSpA model mice. However, it did not apparently inhibit the progression. Furthermore, because vertebral osteoporosis is common comorbid in asSpA, we examined the influence of RANKL or sclerostin inhibition on new bone formation in the mice. The worsening of the bone changes in histological analysis. We are conducting CT scan and checking the reproducibility of bone turnover markers.
|
| Academic Significance and Societal Importance of the Research Achievements |
axSpAの骨新生の原因は明らかでなく、これまで骨新生を直接的に抑制する薬剤はない。IL-22は機序的に関与すると考えれられているが、本研究ではIL-22阻害薬がaxSpAの骨新生抑制の候補標的分子として適当でない可能性があることが示唆された。また、axSpAで問題となる骨粗鬆症に関して、その治療薬である抗RANKL抗体製剤や抗sclerostin抗体製剤の使用の是非は不明であるが、今後確認が必要であるものの、もし骨新生への影響がないとすれば、これらの薬剤の臨床試験を行ううえで有用な基礎データと考えられる。
|
